Key inclusion and exclusion criteria
abnormal neuromuscular transmission, MGFA, Myasthenia Gravis
MYASTHENIA GRAVIS
Men and women aged ≥18 years were eligible for this study if they had Myasthenia Gravis Foundation of America (MGFA) Class II−IVa MG; had a Quantitative Myasthenia Gravis (QMG) score ≥ 12 at screening and baseline; were receiving stable doses of MG treatment before randomization; and were currently not in need of respiratory support (investigator assessment). Participants were also required to have a positive serologic test for anti‐AChR antibodies at screening, with at least one of the following: history of abnormal neuromuscular transmission testing (single‐fiber electromyography or repetitive nerve stimulation), history of positive edrophonium chloride testing, or demonstrated improvement in MG signs on oral cholinesterase inhibitors.Key exclusion criteria included having received rituximab, belimumab, eculizumab, or any monoclonal antibody/Fc‐fusion biologic agent for immunomodulation within 6 months before first dose; tacrolimus within 1 week before the first dose or at any study visit during treatment; parenterally delivered immunoglobulins within 4 weeks before the screening; and having had a thymectomy <12 months before screening, or a splenectomy. Criteria are available at All patients who completed the double‐blind study were eligible to enter the OLE study period.